267 related articles for article (PubMed ID: 22359263)
1. NY-ESO-1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcoma.
Pollack SM; Jungbluth AA; Hoch BL; Farrar EA; Bleakley M; Schneider DJ; Loggers ET; Rodler E; Eary JF; Conrad EU; Jones RL; Yee C
Cancer; 2012 Sep; 118(18):4564-70. PubMed ID: 22359263
[TBL] [Abstract][Full Text] [Related]
2. IL-15 mediated expansion of rare durable memory T cells following adoptive cellular therapy.
Kohli K; Yao L; Nowicki TS; Zhang S; Black RG; Schroeder BA; Farrar EA; Cao J; Sloan H; Stief D; Cranmer LD; Wagner MJ; Hawkins DS; Pillarisetty VG; Ribas A; Campbell J; Pierce RH; Kim EY; Jones RL; Riddell SR; Yee C; Pollack SM
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963013
[TBL] [Abstract][Full Text] [Related]
3. NY-ESO-1 is a sensitive and specific immunohistochemical marker for myxoid and round cell liposarcomas among related mesenchymal myxoid neoplasms.
Hemminger JA; Iwenofu OH
Mod Pathol; 2013 Sep; 26(9):1204-10. PubMed ID: 23599152
[TBL] [Abstract][Full Text] [Related]
4. The potential of the CMB305 vaccine regimen to target NY-ESO-1 and improve outcomes for synovial sarcoma and myxoid/round cell liposarcoma patients.
Pollack SM
Expert Rev Vaccines; 2018 Feb; 17(2):107-114. PubMed ID: 29280411
[TBL] [Abstract][Full Text] [Related]
5. [Pathological significance of NY-ESO-1 expression in the diagnosis of myxoid liposarcoma].
Hei SM; Wei HJ; Chen H; Wang JG
Zhonghua Bing Li Xue Za Zhi; 2019 Mar; 48(3):225-230. PubMed ID: 30831650
[No Abstract] [Full Text] [Related]
6. The cancer-testis antigen NY-ESO-1 is highly expressed in myxoid and round cell subset of liposarcomas.
Hemminger JA; Ewart Toland A; Scharschmidt TJ; Mayerson JL; Kraybill WG; Guttridge DC; Iwenofu OH
Mod Pathol; 2013 Feb; 26(2):282-8. PubMed ID: 22936067
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive adipocytic and neurogenic tissue microarray analysis of NY-ESO-1 expression - a promising immunotherapy target in malignant peripheral nerve sheath tumor and liposarcoma.
Shurell E; Vergara-Lluri ME; Li Y; Crompton JG; Singh A; Bernthal N; Wu H; Eilber FC; Dry SM
Oncotarget; 2016 Nov; 7(45):72860-72867. PubMed ID: 27655679
[TBL] [Abstract][Full Text] [Related]
8. Cancer-testis antigens PRAME and NY-ESO-1 correlate with tumour grade and poor prognosis in myxoid liposarcoma.
Iura K; Kohashi K; Hotokebuchi Y; Ishii T; Maekawa A; Yamada Y; Yamamoto H; Iwamoto Y; Oda Y
J Pathol Clin Res; 2015 Jul; 1(3):144-59. PubMed ID: 27499900
[TBL] [Abstract][Full Text] [Related]
9. MAGEA4 expression in bone and soft tissue tumors: its utility as a target for immunotherapy and diagnostic marker combined with NY-ESO-1.
Iura K; Kohashi K; Ishii T; Maekawa A; Bekki H; Otsuka H; Yamada Y; Yamamoto H; Matsumoto Y; Iwamoto Y; Oda Y
Virchows Arch; 2017 Sep; 471(3):383-392. PubMed ID: 28744588
[TBL] [Abstract][Full Text] [Related]
10. Cancer-testis antigen expression in synovial sarcoma: NY-ESO-1, PRAME, MAGEA4, and MAGEA1.
Iura K; Maekawa A; Kohashi K; Ishii T; Bekki H; Otsuka H; Yamada Y; Yamamoto H; Harimaya K; Iwamoto Y; Oda Y
Hum Pathol; 2017 Mar; 61():130-139. PubMed ID: 27993576
[TBL] [Abstract][Full Text] [Related]
11. Spontaneous tumor-specific humoral and cellular immune responses to NY-ESO-1 in hepatocellular carcinoma.
Korangy F; Ormandy LA; Bleck JS; Klempnauer J; Wilkens L; Manns MP; Greten TF
Clin Cancer Res; 2004 Jul; 10(13):4332-41. PubMed ID: 15240519
[TBL] [Abstract][Full Text] [Related]
12. Antigen-specific immunity in neuroblastoma patients: antibody and T-cell recognition of NY-ESO-1 tumor antigen.
Rodolfo M; Luksch R; Stockert E; Chen YT; Collini P; Ranzani T; Lombardo C; Dalerba P; Rivoltini L; Arienti F; Fossati-Bellani F; Old LJ; Parmiani G; Castelli C
Cancer Res; 2003 Oct; 63(20):6948-55. PubMed ID: 14583496
[TBL] [Abstract][Full Text] [Related]
13. NYESO-1/LAGE-1s and PRAME are targets for antigen specific T cells in chondrosarcoma following treatment with 5-Aza-2-deoxycitabine.
Pollack SM; Li Y; Blaisdell MJ; Farrar EA; Chou J; Hoch BL; Loggers ET; Rodler E; Eary JF; Conrad EU; Jones RL; Yee C
PLoS One; 2012; 7(2):e32165. PubMed ID: 22384167
[TBL] [Abstract][Full Text] [Related]
14. Frequency of NY-ESO-1 and LAGE-1 expression in bladder cancer and evidence of a new NY-ESO-1 T-cell epitope in a patient with bladder cancer.
Sharma P; Gnjatic S; Jungbluth AA; Williamson B; Herr H; Stockert E; Dalbagni G; Donat SM; Reuter VE; Santiago D; Chen YT; Bajorin DF; Old LJ
Cancer Immun; 2003 Dec; 3():19. PubMed ID: 14680360
[TBL] [Abstract][Full Text] [Related]
15. Tumor-infiltrating T cells correlate with NY-ESO-1-specific autoantibodies in ovarian cancer.
Milne K; Barnes RO; Girardin A; Mawer MA; Nesslinger NJ; Ng A; Nielsen JS; Sahota R; Tran E; Webb JR; Wong MQ; Wick DA; Wray A; McMurtrie E; Köbel M; Kalloger SE; Gilks CB; Watson PH; Nelson BH
PLoS One; 2008; 3(10):e3409. PubMed ID: 18923710
[TBL] [Abstract][Full Text] [Related]
16. NY-ESO-1 expression in synovial sarcoma and other mesenchymal tumors: significance for NY-ESO-1-based targeted therapy and differential diagnosis.
Lai JP; Robbins PF; Raffeld M; Aung PP; Tsokos M; Rosenberg SA; Miettinen MM; Lee CC
Mod Pathol; 2012 Jun; 25(6):854-8. PubMed ID: 22388761
[TBL] [Abstract][Full Text] [Related]
17. Antigen-specific in vitro expansion of functional redirected NY-ESO-1-specific human CD8+ T-cells in a cell-free system.
Jakka G; Schuberth PC; Thiel M; Held G; Stenner F; Van Den Broek M; Renner C; Mischo A; Petrausch U
Anticancer Res; 2013 Oct; 33(10):4189-201. PubMed ID: 24122982
[TBL] [Abstract][Full Text] [Related]
18. Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcoma.
Ramachandran I; Lowther DE; Dryer-Minnerly R; Wang R; Fayngerts S; Nunez D; Betts G; Bath N; Tipping AJ; Melchiori L; Navenot JM; Glod J; Mackall CL; D'Angelo SP; Araujo DM; Chow WA; Demetri GD; Druta M; Van Tine BA; Grupp SA; Abdul Razak AR; Wilky B; Iyengar M; Trivedi T; Winkle EV; Chagin K; Amado R; Binder GK; Basu S
J Immunother Cancer; 2019 Oct; 7(1):276. PubMed ID: 31651363
[TBL] [Abstract][Full Text] [Related]
19. Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab.
Yuan J; Adamow M; Ginsberg BA; Rasalan TS; Ritter E; Gallardo HF; Xu Y; Pogoriler E; Terzulli SL; Kuk D; Panageas KS; Ritter G; Sznol M; Halaban R; Jungbluth AA; Allison JP; Old LJ; Wolchok JD; Gnjatic S
Proc Natl Acad Sci U S A; 2011 Oct; 108(40):16723-8. PubMed ID: 21933959
[TBL] [Abstract][Full Text] [Related]
20. NY-ESO-1 protein formulated in ISCOMATRIX adjuvant is a potent anticancer vaccine inducing both humoral and CD8+ t-cell-mediated immunity and protection against NY-ESO-1+ tumors.
Maraskovsky E; Sjölander S; Drane DP; Schnurr M; Le TT; Mateo L; Luft T; Masterman KA; Tai TY; Chen Q; Green S; Sjölander A; Pearse MJ; Lemonnier FA; Chen W; Cebon J; Suhrbier A
Clin Cancer Res; 2004 Apr; 10(8):2879-90. PubMed ID: 15102697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
